BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1131 related articles for article (PubMed ID: 27283257)

  • 1. Correlation Between Histological Diagnosis and Mutational Panel Testing of Thyroid Nodules: A Two-Year Institutional Experience.
    Shrestha RT; Evasovich MR; Amin K; Radulescu A; Sanghvi TS; Nelson AC; Shahi M; Burmeister LA
    Thyroid; 2016 Aug; 26(8):1068-76. PubMed ID: 27283257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Follow-up of atypia and follicular lesions of undetermined significance in thyroid fine needle aspiration cytology.
    Dincer N; Balci S; Yazgan A; Guney G; Ersoy R; Cakir B; Guler G
    Cytopathology; 2013 Dec; 24(6):385-90. PubMed ID: 23078633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Qualifiers of atypia in the cytologic diagnosis of thyroid nodules are associated with different Afirma gene expression classifier results and clinical outcomes.
    Baca SC; Wong KS; Strickland KC; Heller HT; Kim MI; Barletta JA; Cibas ES; Krane JF; Marqusee E; Angell TE
    Cancer Cytopathol; 2017 May; 125(5):313-322. PubMed ID: 28152275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Malignancy rate in thyroid nodules classified as Bethesda category III (AUS/FLUS).
    Ho AS; Sarti EE; Jain KS; Wang H; Nixon IJ; Shaha AR; Shah JP; Kraus DH; Ghossein R; Fish SA; Wong RJ; Lin O; Morris LG
    Thyroid; 2014 May; 24(5):832-9. PubMed ID: 24341462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ThyroSeq v3 for Bethesda III and IV: An institutional experience.
    Desai D; Lepe M; Baloch ZW; Mandel SJ
    Cancer Cytopathol; 2021 Feb; 129(2):164-170. PubMed ID: 33030808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different qualifiers of AUS/FLUS thyroid FNA have distinct BRAF, RAS, RET/PTC, and PAX8/PPARg alterations.
    Bellevicine C; Sgariglia R; Migliatico I; Vigliar E; D'Anna M; Nacchio MA; Serra N; Malapelle U; Bongiovanni M; Troncone G
    Cancer Cytopathol; 2018 May; 126(5):317-325. PubMed ID: 29469940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thyroid nodules classified as atypia or follicular lesions of undetermined significance deserve further research: Analysis of 305 surgically confirmed nodules.
    Turkyilmaz S; Ulusahin M; Celebi B; Cekic AB; Mungan S; Kucuktulu U; Tasdelen A; Guner A; Cinel A
    Cytopathology; 2017 Oct; 28(5):391-399. PubMed ID: 28714532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prediction of malignant risk in the category "atypia of undetermined significance/follicular lesion of undetermined significance" of the Bethesda System for Reporting Thyroid Cytopathology using subcategorization and BRAF mutation results.
    Hyeon J; Ahn S; Shin JH; Oh YL
    Cancer Cytopathol; 2014 May; 122(5):368-76. PubMed ID: 24591408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Testing Has Limited Utility in the Surgical Evaluation of Bethesda III Thyroid Nodules.
    Scola WH; Linhares SM; Handelsman RS; Picado O; Khan ZF; Farrá JC; Lew JI
    J Surg Res; 2021 Dec; 268():209-213. PubMed ID: 34358733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thyroid nodules with atypia or follicular lesions of undetermined significance (Bethesda Category III): importance of ultrasonography and cytological subcategory.
    Rosario PW
    Thyroid; 2014 Jul; 24(7):1115-20. PubMed ID: 24684285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. American College of Radiology thyroid imaging report and data system combined with K-RAS mutation improves the management of cytologically indeterminate thyroid nodules.
    Wu H; Zhang B; Cai G; Li J; Gu X
    PLoS One; 2019; 14(7):e0219383. PubMed ID: 31295281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malignancy rate of atypia of undetermined significance/follicular lesion of undetermined significance in thyroid nodules undergoing FNA in a suburban endocrinology practice: A retrospective cohort analysis.
    Seagrove-Guffey MA; Hatic H; Peng H; Bates KC; Odugbesan AO
    Cancer Cytopathol; 2018 Oct; 126(10):881-888. PubMed ID: 30335212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic Lymphocytic Thyroiditis May Limit the Utility of Molecular Testing in AUS/FLUS Thyroid Nodules.
    Remer LF; Linhares SM; Scola WH; Lew JI
    J Surg Res; 2023 Sep; 289():229-233. PubMed ID: 37148856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the Multi-Gene ThyroSeq Next-Generation Sequencing Assay on Cancer Diagnosis in Thyroid Nodules with Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance Cytology.
    Nikiforov YE; Carty SE; Chiosea SI; Coyne C; Duvvuri U; Ferris RL; Gooding WE; LeBeau SO; Ohori NP; Seethala RR; Tublin ME; Yip L; Nikiforova MN
    Thyroid; 2015 Nov; 25(11):1217-23. PubMed ID: 26356635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk Stratification of Thyroid Nodules With Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance (AUS/FLUS) Cytology Using Ultrasonography Patterns Defined by the 2015 ATA Guidelines.
    Lee JH; Han K; Kim EK; Moon HJ; Yoon JH; Park VY; Kwak JY
    Ann Otol Rhinol Laryngol; 2017 Sep; 126(9):625-633. PubMed ID: 28719972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcategorization of atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS): a study applying Thyroid Imaging Reporting and Data System (TIRADS).
    Yoon JH; Kwon HJ; Kim EK; Moon HJ; Kwak JY
    Clin Endocrinol (Oxf); 2016 Aug; 85(2):275-82. PubMed ID: 26639612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low Malignancy Rates in Fine-Needle Aspiration Cytologies in a Primary Care Setting in Germany.
    Eszlinger M; Ullmann M; Ruschenburg I; Böhme K; Görke F; Franzius C; Adam S; Molwitz T; Landvogt C; Amro B; Hach A; Feldmann B; Graf D; Wefer A; Niemann R; Bullmann C; Klaushenke G; Santen R; Tönshoff G; Ivancevic V; Kögler A; Bell E; Lorenz B; Kluge G; Hartenstein C; Paschke R
    Thyroid; 2017 Nov; 27(11):1385-1392. PubMed ID: 28982301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of repeat cytology with reflex ThyroSeq genomic classifier for indeterminant thyroid cytology.
    O'Conor CJ; Dash RC; Jones CK; Jiang XS
    Cancer Cytopathol; 2022 Jun; 130(6):469-476. PubMed ID: 35045202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Noninvasive Follicular Variant of Papillary Thyroid Carcinoma and the Afirma Gene-Expression Classifier.
    Wong KS; Angell TE; Strickland KC; Alexander EK; Cibas ES; Krane JF; Barletta JA
    Thyroid; 2016 Jul; 26(7):911-5. PubMed ID: 27219469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bethesda Category III, IV, and V Thyroid Nodules: Can Nodule Size Help Predict Malignancy?
    Kiernan CM; Solórzano CC
    J Am Coll Surg; 2017 Jul; 225(1):77-82. PubMed ID: 28223197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.